Zeo Scientifix, Inc balance sheet ZEOX

Annual Quarterly

As of Jun 30, 2026, Zeo Scientifix, Inc had total assets of $4.1 million and total liabilities of $3.5 million. Stockholders' equity was $583,000. It held $2.3 million in cash and investments against $337,000 of total debt, net cash of $1.9 million. The current ratio, current assets divided by current liabilities, was 1.02.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2024 Oct 31, 2025	FY 2024 Oct 31, 2024	FY 2023 Oct 31, 2023	FY 2022 Oct 31, 2022	FY 2021 Oct 31, 2021	FY 2020 Oct 31, 2020	FY 2019 Oct 31, 2019	FY 2018 Oct 31, 2018	FY 2017 Oct 31, 2017
Assets
Cash	2	0 -87.4%	1 -62.6%	2 -53.2%	4 +3356.8%	0 -81.6%	1 +345.7%	0 +208.2%	0 +8.7%	0 +50.9%
Cash and investments	2	0 -87.4%	1 -62.6%	2 -53.2%	4 +3356.8%	0 -81.6%	1 +345.7%	0 +208.2%	0 +8.7%	0 +50.9%
Receivables	0	0 +94.4%	0 +977.8%	0 -67.3%	0 -47.1%	0 +254.4%	0 +12.9%	0 -45.8%	0 -55.2%	0 +9437.3%
Inventory	1	0 +36.5%	0 -25.2%	0 +24.7%	0 +5.8%	0 +60.0%	0 +88.3%	0	0 -100.0%	0 +1102.3%
Total current assets	3	1 -56.5%	1 -47.1%	2 -49.6%	4 +744.2%	1 -38.9%	1 +136.3%	0 +236.9%	0 -62.2%	0 +653.7%
Property and equipment, net	1	1 -0.7%	0 -16.6%	1 -66.0%	2 +51.2%	1 +204.9%	0 +38.7%	0 +4457.2%	0 -89.2%	0 +93.5%
Total assets	4	2 -45.1%	2 -40.9%	3 -55.1%	6 +220.8%	2 +44.9%	1 +105.6%	1 +454.6%	0 -68.9%	0 +439.0%
Liabilities and equity
Total current liabilities	3	3 -28.4%	3 -18.0%	4 -1.3%	4 -1.5%	4 +62.5%	3 +23.4%	2 +54.6%	1 -65.7%	4
Total liabilities	3	3 -26.7%	3 -18.1%	4 -6.7%	4 -6.2%	5	—	—	—	—
Stockholders' equity	1	-1 -14.7%	-2 -33.2%	-1 -165.7%	2 +170.9%	-3 -91.5%	-1 +10.9%	-2 -24.2%	-1 +64.6%	-4 -354.2%
Debt
Debt due within a year	0	0 -63.0%	1 +3.5%	1	—	—	—	0	—	—
Lease liabilities	0	0 -7.1%	0 -89.0%	0 -91.9%	0 -34.2%	1 +146.5%	0	—	—	—
Total debt	0	0 -54.5%	1 -10.6%	1 +55.2%	0 -34.2%	1 +146.5%	0 +79.8%	0	—	—
Net cash	2	-0 -113.5%	-0 -103.7%	1 -67.9%	3 +680.0%	-1 -280.7%	0 +1629.6%	-0	—	—
Ratios
Current ratio	1.02x	0.33x	0.35x	0.55x	1.07x	0.13x	0.33x	0.17x	0.08x	0.07x
Debt to equity	0.58x	—	—	—	0.24x	—	—	—	—	—
Return on equity	—	—	—	—	-470.97%	—	—	—	—	—
Return on assets	—	-308.12%	-286.37%	-251.15%	-143.48%	-659.95%	-943.13%	-267.66%	-2,958.10%	-2,381.27%
Book value per share	0.07	-0.21	-0.26	-0.17	0.26	-0.00	-0.00	-0.00	-0.00	-0.03

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: ZEOX (OTC)
Fiscal year ends: June 30
Incorporated in: NV
Headquarters: Davie, FL
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1557376
Former names: Organicell Regenerative Medicine, Inc. (until Jan 29, 2024); Biotech Products Services & Research, Inc. (until Jun 15, 2018); BESPOKE TRICYCLES INC (until Sep 14, 2015)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.